1. Mayumi, Azusa, Imamura, Toshihiko, Yoshida, Hideki, Yasuda, Takahiko, Iehara, Tomoko. 2023. Leukaemic cells expressing ETV6::FRK are sensitive to dasatinib in vivo. In EJHaem, 4, 751-755. doi:10.1002/jha2.701. https://pubmed.ncbi.nlm.nih.gov/37601849/
2. Nault, Jean-Charles, Couchy, Gabrielle, Balabaud, Charles, Letouzé, Eric, Zucman-Rossi, Jessica. 2016. Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation. In Gastroenterology, 152, 880-894.e6. doi:10.1053/j.gastro.2016.11.042. https://pubmed.ncbi.nlm.nih.gov/27939373/
3. Brauer, Patrick M, Tyner, Angela L. 2009. RAKing in AKT: a tumor suppressor function for the intracellular tyrosine kinase FRK. In Cell cycle (Georgetown, Tex.), 8, 2728-32. doi:. https://pubmed.ncbi.nlm.nih.gov/19652529/
4. Hua, Lei, Wang, Guanghui, Wang, Zhen, Zhu, Yufu, Yu, Rutong. 2019. Activation of STAT1 by the FRK tyrosine kinase is associated with human glioma growth. In Journal of neuro-oncology, 143, 35-47. doi:10.1007/s11060-019-03143-w. https://pubmed.ncbi.nlm.nih.gov/30993511/
5. Ogunbolude, Yetunde, Dai, Chenlu, Bagu, Edward T, Bonham, Keith, Lukong, Kiven Erique. 2017. FRK inhibits breast cancer cell migration and invasion by suppressing epithelial-mesenchymal transition. In Oncotarget, 8, 113034-113065. doi:10.18632/oncotarget.22958. https://pubmed.ncbi.nlm.nih.gov/29348886/
6. Zhang, Li, Yang, Yongfeng, Chai, Li, Chen, Fei, Li, Weimin. 2019. FRK plays an oncogenic role in non-small cell lung cancer by enhancing the stemness phenotype via induction of metabolic reprogramming. In International journal of cancer, 146, 208-222. doi:10.1002/ijc.32530. https://pubmed.ncbi.nlm.nih.gov/31251822/
智鼠故事 
